Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis

Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis

Background: Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still unclear. Methods: To identify clinica...

Full description

Bibliographic Details
Main Authors: Gaëtan Des Guetz, Thierry Landre, Marc A. Bollet, Muriel Mathonnet, Laurent Quéro
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
meta-analysis
randomized
rectal
radiotherapy
oxaliplatin
neoadjuvant
Online Access:https://www.mdpi.com/2072-6694/13/23/6035

Internet

https://www.mdpi.com/2072-6694/13/23/6035

Similar Items